NCT03441113
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03441113
Title Extended Access of Momelotinib in Adults With Myelofibrosis
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sierra Oncology, Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | ROU | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | CAN | BGR | BEL | AUT | AUS

Facility Status City State Zip Country Details
GSK Investigational Site Scottsdale Arizona 53226 United States Details
GSK Investigational Site Orange California 97239 United States Details
GSK Investigational Site Stanford California 94305-5821 United States Details
GSK Investigational Site Aurora Colorado 80045 United States Details
GSK Investigational Site Jacksonville Florida 32224 United States Details
GSK Investigational Site Tampa Florida 33612 United States Details
GSK Investigational Site Atlanta Georgia 30322 United States Details
GSK Investigational Site Baltimore Maryland 21229-5299 United States Details
GSK Investigational Site Boston Massachusetts 02215 United States Details
GSK Investigational Site Rochester Minnesota 55905 United States Details
GSK Investigational Site St Louis Missouri 63130 United States Details
GSK Investigational Site Hackensack New Jersey 07601 United States Details
GSK Investigational Site The Bronx New York 10467 United States Details
GSK Investigational Site Cleveland Ohio 44195 United States Details
GSK Investigational Site South Brisbane Queensland 4101 Australia Details
GSK Investigational Site Bedford Park South Australia 5000 Australia Details
GSK Investigational Site Frankston Victoria 31 99 Australia Details
GSK Investigational Site Melbourne Victoria 3004 Australia Details
GSK Investigational Site Melbourne Victoria 3050 Australia Details
GSK Investigational Site Perth Western Australia 6000 Australia Details
GSK Investigational Site Linz 4020 Austria Details
GSK Investigational Site Vienna 1090 Austria Details
GSK Investigational Site Antwerp 2030 Belgium Details
GSK Investigational Site Bruges 8000 Belgium Details
GSK Investigational Site Leuven 3000 Belgium Details
GSK Investigational Site Liège 4000 Belgium Details
GSK Investigational Site Pleven 5800 Bulgaria Details
GSK Investigational Site Rousse 7002 Bulgaria Details
GSK Investigational Site Sofia 01431 Bulgaria Details
GSK Investigational Site Sofia 1756 Bulgaria Details
GSK Investigational Site Toronto Ontario M5G 2M9 Canada Details
GSK Investigational Site Montreal Quebec H3H 2R9 Canada Details
GSK Investigational Site Montreal Quebec H3T 1E2 Canada Details
GSK Investigational Site Aalborg 9000 Denmark Details
GSK Investigational Site Herlev 2100 Denmark Details
GSK Investigational Site Le Mans 72037 France Details
GSK Investigational Site Lille 13273 France Details
GSK Investigational Site Marseille 13273 France Details
GSK Investigational Site Paris 75475 France Details
GSK Investigational Site Pessac 33604 France Details
GSK Investigational Site Pierre-Bénite 69495 France Details
GSK Investigational Site Toulouse 31059 France Details
GSK Investigational Site Aachen 52074 Germany Details
GSK Investigational Site Cologne 50937 Germany Details
GSK Investigational Site Dresden 01307 Germany Details
GSK Investigational Site Halle 06120 Germany Details
GSK Investigational Site Leipzig 04103 Germany Details
GSK Investigational Site Lübeck 79106 Germany Details
GSK Investigational Site Mainz 55131 Germany Details
GSK Investigational Site Budapest 1083 Hungary Details
GSK Investigational Site Budapest 1097 Hungary Details
GSK Investigational Site Debrecen 4032 Hungary Details
GSK Investigational Site Győr 9024 Hungary Details
GSK Investigational Site Kaposvár 7400 Hungary Details
GSK Investigational Site Nyíregyháza 4400 Hungary Details
GSK Investigational Site Tatabánya 2800 Hungary Details
GSK Investigational Site Afula 18101 Israel Details
GSK Investigational Site Ashkelon 7830604 Israel Details
GSK Investigational Site Haifa 3436212 Israel Details
GSK Investigational Site Jerusalem 9112001 Israel Details
GSK Investigational Site Kfar Saba 44281 Israel Details
GSK Investigational Site Bologna 40138 Italy Details
GSK Investigational Site Florence 50134 Italy Details
GSK Investigational Site Genova 16132 Italy Details
GSK Investigational Site Milan 20122 Italy Details
GSK Investigational Site Monza 20900 Italy Details
GSK Investigational Site Naples 80131 Italy Details
GSK Investigational Site Pesaro 61122 Italy Details
GSK Investigational Site Rionero in Vulture PZ 85028 Italy Details
GSK Investigational Site Roma 00161 Italy Details
GSK Investigational Site Torino 10126 Italy Details
GSK Investigational Site Torino 10128 Italy Details
GSK Investigational Site Verona 37134 Italy Details
GSK Investigational Site Maastricht 6229 ER Netherlands Details
GSK Investigational Site Brzozów 36-200 Poland Details
GSK Investigational Site Chorzów 41-500 Poland Details
GSK Investigational Site Gdansk 80-214 Poland Details
GSK Investigational Site Krakow 30-688 Poland Details
GSK Investigational Site Lublin 20-081 Poland Details
GSK Investigational Site Opole 45-061 Poland Details
GSK Investigational Site Poznan 60-631 Poland Details
GSK Investigational Site Brasov 500152 Romania Details
GSK Investigational Site Bucharest 022328 Romania Details
GSK Investigational Site Bucharest 030171 Romania Details
GSK Investigational Site Cluj-Napoca 400124 Romania Details
GSK Investigational Site Craiova 200143 Romania Details
GSK Investigational Site Iași 700111 Romania Details
GSK Investigational Site Singapore 169608 Singapore Details
GSK Investigational Site Singapore 188770 Singapore Details
GSK Investigational Site Busan 48108 South Korea Details
GSK Investigational Site Daegu 700-721 South Korea Details
GSK Investigational Site Seoul 03080 South Korea Details
GSK Investigational Site Seoul 03722 South Korea Details
GSK Investigational Site Seoul 135-710 South Korea Details
GSK Investigational Site Seoul 137-701 South Korea Details
GSK Investigational Site Barcelona 08003 Spain Details
GSK Investigational Site Barcelona 08035 Spain Details
GSK Investigational Site Barcelona 08916 Spain Details
GSK Investigational Site Madrid 28034 Spain Details
GSK Investigational Site Madrid 28041 Spain Details
GSK Investigational Site Madrid 28222 Spain Details
GSK Investigational Site Pamplona 31008 Spain Details
GSK Investigational Site Zaragoza 50012 Spain Details
GSK Investigational Site Kaohsiung City 807 Taiwan Details
GSK Investigational Site Kaohsiung City 833 Taiwan Details
GSK Investigational Site Taipei 100 Taiwan Details
GSK Investigational Site Taoyuan 333 Taiwan Details
GSK Investigational Site Airdrie ML6 0JS United Kingdom Details
GSK Investigational Site Bristol BS2 8ED United Kingdom Details
GSK Investigational Site Cardiff CF14 4XW United Kingdom Details
GSK Investigational Site London W12 0HS United Kingdom Details
GSK Investigational Site Oxford OX3 7LE United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field